Pulocimab | m-entrepreneurship.com

Product Name :
Pulocimab

Search keywords :
Pulocimab

drugId :
null

Target Vo:
Vascular endothelial growth factor receptor 2

Target Vo Short Name :
VEGFR2

Moa_Name:
Vascular endothelial growth factor receptor 2 antagonists

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Kang Rong Dongfang (Guangdong) Pharmaceutical Co Ltd

Active Company_Name :
Akeso Pharmaceuticals Inc

Active Indication_Name:
Esophageal Neoplasms

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Phase 3 Clinical

China Highest Status:
Phase 3 Clinical

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Naxitamab custom synthesis
Alefacept Autophagy
AMPK beta 1 Antibody: AMPK beta 1 Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 30 kDa, targeting to AMPK beta 1. It can be used for WB,IHC-P,FC,IP assays with tag free, in the background of Human, Mouse, Rat.

Author: Betaine hydrochloride

Related Posts